Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM).

Nicola Silvestris, Oronzo Brunetti, Alessandro Bittoni, Ivana Cataldo, Domenico Corsi, Stefano Crippa, Mirko D'Onofrio, Michele Fiore, Elisa Giommoni, Michele Milella, Raffaele Pezzilli, Enrico Vasile, Michele Reni

Research output: Contribution to journalReview articlepeer-review

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death in women (7%) and the sixth in men (5%) in Italy, with a life expectancy of around 5% at 5 years. From 2010, the Italian Association of Medical Oncology (AIOM) developed national guidelines for several cancers. In this report, we report a summary of clinical recommendations of diagnosis, treatment and follow-up of PDAC, which may guide physicians in their current practice. A panel of AIOM experts in upper gastrointestinal cancer malignancies discussed the available scientific evidence supporting the clinical recommendations.

Original languageEnglish
Article number1681
JournalCancers
Volume12
Issue number6
DOIs
Publication statusPublished - Jun 24 2020

Fingerprint Dive into the research topics of 'Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM).'. Together they form a unique fingerprint.

Cite this